GLP-1 Joint Pain and Knee Osteoarthritis: What the Research Actually Shows

The 30-second summary

• In the STEP-9 trial, semaglutide cut knee osteoarthritis pain almost twice as much as placebo over 68 weeks, and the group was about 82% women.
• A 2026 Cell Metabolism study suggested a cartilage benefit that held up even after controlling for weight loss, pointing to a second mechanism beyond simple unloading.
• GLP-1 medicines are not FDA-approved for osteoarthritis, and a minority of women report transient joint aches while losing weight quickly. What protects the joint long term is the muscle around it.

Why GLP-1, joint pain and knee osteoarthritis belong in the same conversation

If you are a woman on a GLP-1 medicine, your knees were probably never in the brochure. The headline is always the scale. Yet for a large share of women starting Ozempic, Wegovy, Mounjaro or Zepbound, the quiet daily complaint is a stiff, aching knee, and the quiet daily hope is that losing weight will finally let them climb stairs without negotiating.

This is not a niche worry. Knee osteoarthritis is one of the leading causes of pain and disability in midlife and beyond, and it is not gender-neutral. Radiographic knee osteoarthritis is roughly three times more common in women aged 45 to 64 than in men of the same age, and the gap widens after menopause. Cartilage is an estrogen-sensitive tissue, so when estrogen falls in the menopausal transition, the joint loses some of its built-in protection. The result is a familiar pattern: knee pain that arrives, or sharpens, in exactly the years when many women are also being offered a GLP-1.

So the real question is not "does Ozempic cause joint pain." It is "what does a GLP-1 actually do to a knee, for better and for worse," and the answer in 2026 is more interesting than most copy admits.

What STEP-9 actually found

The most important piece of evidence is the STEP-9 trial, published in the New England Journal of Medicine on 30 October 2024. Researchers enrolled adults with obesity and moderate-to-severe knee osteoarthritis and randomized them to once-weekly semaglutide 2.4 mg or placebo, alongside diet and activity advice, for 68 weeks. The trial population was about 82% women, which is unusual and welcome: for once the dataset looks like the people actually living with this condition.

The pain results were clear. On the WOMAC pain scale, where a bigger drop is better, the semaglutide group fell by 41.7 points versus 27.5 in the placebo group, an estimated treatment difference of roughly 14 points. Physical function improved more on semaglutide too. Body weight fell 13.7% on semaglutide against 3.2% on placebo. In plain terms, women who took the medicine hurt less and moved better, and they did so by a margin that matters in daily life, not just on a chart.

This is the strongest reason to take the joint story seriously. It is also why some clinicians now talk about a possible knock-on benefit: less reliance on daily anti-inflammatory tablets, which carry their own gut and kidney costs. STEP-9 did not prove that, but the direction is encouraging.

The mechanism: less load, and maybe less inflammation

There are two honest explanations for why a knee feels better, and they are not rivals. They stack.

The first is mechanical and well established. Your knee carries a multiple of your body weight with every step. Classic biomechanics work found that each pound lost takes roughly four pounds of load off the knee per stride. Multiply that across thousands of steps a day and even modest weight loss becomes a meaningful reduction in the pounding a worn joint absorbs. This is the part everyone already understands: lighter body, lighter footfall, calmer knee.

The second explanation is newer and more surprising. A 2026 study in Cell Metabolism reported that semaglutide slowed osteoarthritis progression in an obese-mouse model, with less cartilage breakdown, fewer bony spurs and less joint inflammation. The striking finding was that part of the effect persisted after researchers controlled for weight, supported by a diet-controlled pilot designed to strip out the appetite-suppression and weight-loss effect. The proposed mechanism is metabolic: the drug appears to reprogram how cartilage cells generate energy under inflammatory stress, via an AMPK-PFKFB3 pathway, nudging them away from a damaging glycolytic state.

A word of caution belongs here. This is early, largely preclinical science, not a human cure. But it fits a wider theme in this category, which is that GLP-1 medicines seem to lower inflammation through routes that are not only about fat. We explore that thread in our piece on how GLP-1 medications affect inflammation, and it may help explain joint, heart and metabolic benefits at once.

The honest part: not approved for arthritis, and some aches go the other way

Two caveats keep this article credible.

First, no GLP-1 is FDA-approved to treat osteoarthritis. STEP-9 is one trial in people who also had obesity. Any joint benefit you experience is welcome, but it is a bonus, not the labeled purpose of the prescription. Treat it that way with your clinician.

Second, a minority of women report new joint aches in the early months, usually while weight is coming off fastest. The most likely reasons are mundane: rapid changes in load and posture, suddenly doing more movement than your joints are used to, or an existing arthritic joint becoming noticeable once other discomforts fade. In the trials, arthralgia rates were broadly similar to placebo, so this is not a hidden epidemic. If aches are sharp, one-sided, or come with swelling, that is a reason to call your prescriber rather than push through.

What protects the joint is the muscle around it

Here is the part the scale will never tell you. A knee is only as stable as the quadriceps, hamstrings and glutes that hold it. Lose weight fast without protecting muscle and you can end up lighter but less stable, which is the opposite of what an arthritic knee needs.

On a GLP-1, appetite drops and protein is the first thing many women under-eat. That is the wrong trade for your joints. Prioritizing protein and resistance work is the single most reliable thing you can do to keep the supporting muscle while the load comes off. Our guides on protecting muscle while losing weight on a GLP-1, protein targets on a GLP-1 and strength training during treatment lay out the practical version. It is also worth knowing that the same months can affect the skeleton, which is why we cover bone density on GLP-1 medications as a companion read. Strong muscle, steady bone, calmer joint: that is the outcome worth chasing, far more than a number on the floor.

What Steady does with this

• Steady tracks 14 GLP-1 symptoms, so if joint aches appear you can see whether they cluster with your fastest weight-loss weeks or your activity changes, instead of guessing.
• Steady keeps your protein and strength front and center, because the muscle around a joint is what holds it steady, and that is exactly the thing GLP-1 medicines put at risk.
• Steady turns a month into one clean page for your prescriber, so a conversation about knee pain, dose and movement starts with real data rather than memory. Steady does not diagnose or treat osteoarthritis.

Read next: How GLP-1 medications affect inflammation, Protecting muscle while losing weight on a GLP-1, Strength training on a GLP-1

For the news brief on the trial behind this story, see semaglutide and knee osteoarthritis pain.

Sources

1. Bliddal H, et al. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis. New England Journal of Medicine, 30 October 2024 (STEP-9). NEJM
2. Novo Nordisk. STEP-9 results published in NEJM demonstrated semaglutide reduced knee osteoarthritis-related pain in people with obesity. PR Newswire, October 2024. PR Newswire
3. Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism. Cell Metabolism, 2026. Cell Metabolism
4. Messier SP, et al. Weight loss reduces knee-joint loads in overweight and obese older adults with knee osteoarthritis. Arthritis & Rheumatism, 2005. PubMed
5. The intersection of aging and estrogen in osteoarthritis. npj Women's Health, 2025. Nature

Medical disclaimer: Articles in the Steady research hub are educational, not medical advice. GLP-1 medicines are not approved to treat osteoarthritis, and decisions about your medication, joint symptoms or activity should be made with a qualified clinician who knows your history. See our full medical disclaimer.